Printer Friendly

PFIZER RECEIVES MARKETING APPROVAL FOR NORVASC

 PFIZER RECEIVES MARKETING APPROVAL FOR NORVASC
 NEW YORK, Aug. 3 /PRNewswire/ -- Pfizer Inc (NYSE: PFE) announced


today that it has received final approval from the Food and Drug Administration for Norvasc (amlodipine besylate) (see note), its new calcium channel blocker, for the once-daily treatment of hypertension and angina.
 "Norvasc is an important addition to Pfizer's portfolio of new products," said William C. Steere, Jr., Pfizer chairman and chief executive officer. "Norvasc has been available since January 1990 in international markets, where it has performed exceptionally well. In fact, it is the number one calcium channel blocker in a number of countries."
 The company expects to launch Norvasc early in the fourth quarter of this year. The product will join Zoloft (note), Pfizer's new serotonin reuptake inhibitor class antidepressant, and Zithromax (note), a new azalide once-daily antibiotic, in the list of new products Pfizer has launched this year.
 Pfizer Inc is a research-based, diversified health care company with global operations. The company reported sales of approximately $6.95 billion for 1991.
 (Note: Norvasc, Zoloft and Zithromax are registered trademarks of Pfizer Inc.)
 -0- 8/3/92
 /CONTACT: A. A. Biesada, 212-573-2055, or Rick Honey, 212-573-2051, both of Pfizer/
 (PFE) CO: Pfizer Inc. ST: New York IN: MTC SU:


KD -- NY076 -- 6291 08/03/92 16:03 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 3, 1992
Words:216
Previous Article:CIGNA REPORTS SECOND QUARTER RESULTS
Next Article:WWP BOARD DECLARES COMMON AND PREFERRED STOCK DIVIDENDS
Topics:


Related Articles
Pfizer Inc: New Product Success Foundation for Strong International and U.S. Growth, Company Tells Analysts
Pfizer Drug Norvasc Demonstrated Safe In Sickest Heart Patients
Pfizer Sees Unprecedented Product Opportunities Based On Innovative R&D, Global Marketing Strengths, Company Tells Analysts
Pfizer CCB Norvasc Demonstrates 31 Percent Reduction in Cardiovascular Events, New Study Shows.
/C O R R E C T I O N -- Pfizer Inc/.
U.S. Appeals Court Upholds Patent for Pfizer's Norvasc.
FDA to Re-Evaluate Dr. Reddy Application On Amlodipine Maleate, Pfizer Says.
Largest Long-Term Hypertension Study Using Pfizer's Norvasc Provides New Insights Into Cardiovascular Health.
Pfizer Statement on Norvasc Patent Case.
Daiichi Sankyo, Inc. Announces Filing of New Drug Application for Amlodipine Besylate / Olmesartan Medoxomil Combination for the Treatment of...

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters